- Partnership with peak body to promote SleepCheck as a screening test for obstructive sleep apnoea (OSA) in people living with diabetes
- ~1.2m Australians live with type 2 diabetes and 50-80% of those also suffer from OSA
- Delivers validation of SleepCheck application from a highly respected organisation
Brisbane, Australia, 28 September 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease is pleased to report a partnership with Diabetes Queensland to promote its mobile medical application SleepCheck and raise awareness of the lack of sleep and sleep apnoea in people living with diabetes.
Approximately 1.2 million people in Australia live with type 2 diabetes and there are an estimated 500,000 undiagnosed cases. Studies have shown that there are strong links between type 2 diabetes and obstructive sleep apnoea (OSA), with 50%-80% of people living with type 2 experiencing OSA.
Further, not getting adequate sleep also places people at an increased risk of developing type 2 diabetes due to their body not properly being able to regulate glucose levels.
Untreated OSA causes stress on the body and increases the risk of cardiovascular issues (high blood pressure, stroke and heart attacks), diabetes, depression and being involved in accidents.
As part of the agreement, ResApp will work with Diabetes Queensland to raise awareness of these risks and promote its SleepCheck application as a screening tool for people with diabetes that may be suffering from OSA.
SleepCheck is ResApp’s easy to use, direct-to-consumer mobile medical application that uses accurate algorithms to assess a person’s risk of OSA by analysing breathing and snoring sounds during sleep. It requires no accessories or hardware other than the user’s smartphone to make an assessment.
Both parties have collaboratively launched a dedicated SleepCheck website (www.sleepcheckapp.com/diabetes) for people with diabetes, with diabetes-related content provided by Diabetes Queensland.
The partnership will allow ResApp to expedite uptake of its SleepCheck application in Australia and provides invaluable marketing and exposure with a large potential user base.
SleepCheck is clinically validated and available to purchase for $7.99 on the iOS App Store. The application is approved by the Therapeutic Goods Administration (TGA) for ARTG Listing as a Class 1 medical device.
CEO and Managing Director Dr Tony Keating said: “This partnership with Diabetes Queensland is excellent validation of our SleepCheck technology which offers people with diabetes the only clinical grade, regulatory approved screen app that can be used in the comfort of their own home. This puts them immediately on a path to treatment, which could potentially improve their quality of life and reduce the risk of adverse health outcomes.”
Diabetes Queensland CEO Sturt Eastwood said: “Diabetes can lead to serious and life threatening health complications. The partnership with ResApp will help our community understand the impact of sleep on their diabetes management which in turn should improve their wellbeing and help delay or prevent complications.”
Diabetes is a serious chronic health condition which occurs when there is too much glucose in the blood. Over time high glucose levels can damage the body’s blood vessels and nerves, leading to long term health complications such as heart, kidney and eye disease, and nerve damage in the feet. Around 1.2m Australians live with type 2 diabetes and a further 500,000 are undiagnosed. 280 Australians develop diabetes every day.
About Obstructive Sleep Apnoea
Obstructive sleep apnoea is a serious medical condition characterised by the intermittent partial or entire obstruction of the upper airway, which prevents air from flowing to the lungs for ten seconds or longer during sleep. In some cases, this can happen more than 30 times per hour all night. This causes daytime tiredness, reduced productivity and an impaired immune system, and has been linked to serious complications such as heart disease, hypertension, stroke and type 2 diabetes. Sleep apnoea affects nearly a third of all men, and a fifth of all women.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.